- Home
- CAMT vs GH Comparison
CAMT vs GH Comparison
Compare CAMT & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAMT
- GH
- Stock Information
- Founded
- CAMT 1987
- GH 2011
- Country
- CAMT Israel
- GH United States
- Employees
- CAMT N/A
- GH N/A
- Industry
- CAMT Electronic Components
- GH Medical Specialities
- Sector
- CAMT Technology
- GH Health Care
- Exchange
- CAMT Nasdaq
- GH Nasdaq
- Market Cap
- CAMT 4.3B
- GH 4.9B
- IPO Year
- CAMT 2000
- GH 2018
- Fundamental
- Price
- CAMT $105.72
- GH $108.29
- Analyst Decision
- CAMT Strong Buy
- GH Strong Buy
- Analyst Count
- CAMT 11
- GH 21
- Target Price
- CAMT $116.36
- GH $75.48
- AVG Volume (30 Days)
- CAMT 514.1K
- GH 3.6M
- Earning Date
- CAMT 11-10-2025
- GH 10-29-2025
- Dividend Yield
- CAMT 1.27%
- GH N/A
- EPS Growth
- CAMT N/A
- GH N/A
- EPS
- CAMT 1.01
- GH N/A
- Revenue
- CAMT $485,241,000.00
- GH $902,569,000.00
- Revenue This Year
- CAMT $17.39
- GH $33.95
- Revenue Next Year
- CAMT $8.22
- GH $25.77
- P/E Ratio
- CAMT $102.10
- GH N/A
- Revenue Growth
- CAMT 21.12
- GH 30.38
- 52 Week Low
- CAMT $47.41
- GH $29.91
- 52 Week High
- CAMT $129.41
- GH $112.43
- Technical
- Relative Strength Index (RSI)
- CAMT 48.85
- GH 74.35
- Support Level
- CAMT $91.91
- GH $98.23
- Resistance Level
- CAMT $104.34
- GH $112.43
- Average True Range (ATR)
- CAMT 5.39
- GH 5.58
- MACD
- CAMT -0.31
- GH 0.32
- Stochastic Oscillator
- CAMT 49.71
- GH 80.42
About CAMT Camtek Ltd.
Camtek Ltd is engaged in the manufacturing of metrology and inspection equipment and software solutions for the semiconductor industry. Its systems inspect wafers for various semiconductor market segments, including Advanced Packaging, Heterogenous Integration (HI), Compound Semiconductors, Memory, and foundries among others. Geographically, it derives maximum revenue from China followed by Asia Pacific, Korea, United States, and Europe. The company's products and services include Surface Inspection, Bump Inspection and Metrology, and others.
About GH Guardant Health Inc.
Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.